Bright Minds Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRUG research report →
Range $145 – $220
Price Chart
About the company
Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
- CEO
- Ian McDonald
- IPO
- 2021
- Employees
- 26
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DRUG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $472.23M
- P/E
- -23.86
- PEG
- 0.32
- P/S
- 0.00
- P/B
- 2.21
- EV/EBITDA
- -9.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -12.56%
- ROIC
- -12.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,937,584
- Net Income
- $-12,229,348-336.5%
- EPS
- $-1.78-173.8%
- OCF Growth
- -369.8%
- FCF Growth
- -369.8%
- 52W High
- $123.75
- 52W Low
- $47.60
- 50D MA
- $68.60
- 200D MA
- $76.32
- Beta
- 0.09
- RSI (14)
- 24
- Avg Volume
- 155.32K
No earnings-call transcripts are available for DRUG yet.
- Free Float
- 62.4%
- Shares Outstanding
- 9.79M
- Float Shares
- 6.11M
of shares held by institutions
102 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jupiter Topco LLC | 1.35M | ▲ 1.35M |
| Janus Henderson Group Ltd. | 1.28M | ▲ 128.33K |
| Cormorant Asset Management, LP | 900.00K | ▼ 159.33K |
| Blackrock, Inc. | 686.18K | ▲ 64.25K |
| Vivo Capital, LLC | 557.17K | 0 |
| Vestal Point Capital, LP | 545.00K | ▲ 52.68K |
| Braidwell LP | 483.82K | ▼ 55.89K |
| Driehaus Capital Management LLC | 433.38K | ▲ 862 |
| Balyasny Asset Management L.P. | 345.05K | ▲ 47.90K |
| Adage Capital Partners Gp, L.L.C. | 335.00K | ▼ 160.74K |
| Point72 Asset Management, L.P. | 327.42K | ▲ 327.42K |
| Deerfield Management Company, L.P. (Series C) | 283.00K | 0 |
Held by 41 ETFs
Biggest fund positions in DRUG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Cormorant Asset Management, LP | sell | 109,331 |
| Nov 4, 24 | Cormorant Asset Management, LP | buy | 184,331 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 3,107 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 7,150 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 39,743 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 4,609 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 19,169 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,700 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,600 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 8,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRUG coverage
Recent articles, reports, and earnings notes.
No research on DRUG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRUG report →Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
globenewswire.com · Sep 30
Bright Minds Biosciences to Present at Upcoming Conferences
globenewswire.com · Sep 4
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
zacks.com · Aug 27
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
zacks.com · Aug 26
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
zacks.com · Aug 10
Vistagen Appoints Douglas J. Williamson to its Board of Directors
globenewswire.com · Jul 31
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
zacks.com · Jul 23
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
zacks.com · Jul 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.